945 results on '"Baiocchi, Robert A,"'
Search Results
202. PRMT5 as a druggable target for glioblastoma therapy
203. EXTH-26. PRMT5 AS A DRUGGABLE TARGET FOR GLIOBLASTOMA THERAPY
204. A phase 1b/pharmacokinetic trial of PTC299, a novel post-transcriptional VEGF inhibitor, for AIDS-related Kaposi’s sarcoma: AIDS Malignancy Consortium trial 059
205. Correction: PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis
206. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
207. Abstract 5663: A potential role for NKG2A to influence post-transplant outcomes in multiple myeloma
208. Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma
209. Selective PRMT5 inhibition suppresses inflammatory T cell responses and autoimmunity.
210. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas
211. Frequency and clinical correlates of elevated plasma Epstein‐Barr virus DNA at diagnosis in peripheral T‐cell lymphomas
212. PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis
213. Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status
214. PRMT5 Targets Tumor Suppressor Micro RNAs to Regulate Cyclin D1 and c-MYC in Mantle Cell Lymphoma
215. PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas
216. Protein Arginine Methyltransferase 5 Regulates WNT/β-Catenin Target Gene Expression in at Multiple Levels
217. Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial
218. BET Bromodomain Inhibition Selectively Targets the Epstein-Barr Virus Oncogene LMP1 While Promoting Virus-Specific, Adaptive Anti-Tumor Activity
219. STMC-07. PRMT5-PTEN MOLECULAR PATHWAY REGULATES SENESCENCE AND SELF-RENEWAL OF GLIOBLASTOMA NEUROSPHERES
220. The Epstein-Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development1
221. PU.1 and epigenetic signals modulate 1,25‐dihydroxyvitamin D3 and C/EBPα regulation of the human cathelicidin antimicrobial peptide gene in lung epithelial cells.
222. Postinfusion PD-1+CD8+CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
223. Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses
224. Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial
225. Targeting EBV Encoded Viral Kinases with GCV, AZT, Rituximab and Dexamethasone (GARD) Results in Durable Responses in Patients with CNS Lymphoproliferative Disease
226. Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study
227. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases
228. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial
229. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma
230. Abstract 2845: PRMT5-PTEN molecular pathway regulates senescence and self-renewal of Glioblastoma stem-like cells
231. NKp80 Defines a Critical Step during Human Natural Killer Cell Development
232. A phase 1 trial of vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced stage head and neck squamous cell carcinoma.
233. Epigenetic modulation of inflammatory T cell responses
234. Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma
235. Post-transplant Lymphoproliferative Disorder (PTLD): Infection, Cancer?
236. Murine Models of Epstein-Barr Virus–Associated Lymphomagenesis
237. PRMT5 Is Upregulated in HTLV-1-Mediated T-Cell Transformation and Selective Inhibition Alters Viral Gene Expression and Infected Cell Survival
238. Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium
239. Blastic Plasmacytoid Dendritic Cell Neoplasm: A Single-Center Experience Documenting Frequent CNS Involvement
240. NTCT-04SPINAL CORD TOXICITY FROM INTRATHECAL CHEMOTHERAPY: A CASE WITH CLINICOPATHOLOGIC CORRELATION
241. A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4⁺ T-cells
242. 21 - Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder
243. Update on Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials
244. New and Updated Results from a Multicenter, Open-Label, Global Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab (R) or Rituximab and Chemotherapy (R+CT) (ALLELE)
245. PRMT5 as a druggable target for glioblastoma therapy.
246. Synthesis, biological evaluation, and radioiodination of halogenated closo-carboranyl thymidine analogues1
247. PRMT5 Initiates an Epigenetic Program That Promotes Progression of Chronic Lymphocytic Leukemia
248. Malignant NK Cells from EBV(+) Human Extranodal NK/T Cell Lymphoma Exhibit Features of a Distinct NK Cell Developmental Subset Found in Mucosal Associated Lymphoid Tissue
249. Phase II trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma
250. Elevated plasma Epstein-Barr virus DNA at diagnosis predicts a poor prognosis in peripheral T-cell lymphomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.